BACKGROUND: In 2008, the US Food and Drug Administration (FDA) issued a Guidance for Industry statement formally recognizing (during drug development) the conjoined nature of type 2 diabetes (T2D) and cardiovascular disease (CVD), which has precipitated an urgent need for panels of markers (and means of analysis) that are able to differentiate subtypes of CVD in the context of T2D. Here, we explore the possibility of creating such panels using the working hypothesis that proteins, in addition to carrying time-cumulative marks of hyperglycemia (e.g., protein glycation in the form of Hb A(₁c)), may carry analogous information with regard to systemic oxidative stress and aberrant enzymatic signaling related to underlying pathobiologies involved in T2D and/or CVD. METHODS: We used mass spectrometric immunoassay to quantify, in targeted fashion, relative differences in the glycation, oxidation, and truncation of 11 specific proteins. RESULTS: Protein oxidation and truncation (owing to modified enzymatic activity) are able to distinguish between subsets of diabetic patients with or without a history of myocardial infarction and/or congestive heart failure where markers of glycation alone cannot. CONCLUSION: Markers based on protein modifications aligned with the known pathobiologies of T2D represent a reservoir of potential cardiovascular markers that are needed to develop the next generation of antidiabetes medications.
BACKGROUND: In 2008, the US Food and Drug Administration (FDA) issued a Guidance for Industry statement formally recognizing (during drug development) the conjoined nature of type 2 diabetes (T2D) and cardiovascular disease (CVD), which has precipitated an urgent need for panels of markers (and means of analysis) that are able to differentiate subtypes of CVD in the context of T2D. Here, we explore the possibility of creating such panels using the working hypothesis that proteins, in addition to carrying time-cumulative marks of hyperglycemia (e.g., protein glycation in the form of Hb A(₁c)), may carry analogous information with regard to systemic oxidative stress and aberrant enzymatic signaling related to underlying pathobiologies involved in T2D and/or CVD. METHODS: We used mass spectrometric immunoassay to quantify, in targeted fashion, relative differences in the glycation, oxidation, and truncation of 11 specific proteins. RESULTS: Protein oxidation and truncation (owing to modified enzymatic activity) are able to distinguish between subsets of diabeticpatients with or without a history of myocardial infarction and/or congestive heart failure where markers of glycation alone cannot. CONCLUSION: Markers based on protein modifications aligned with the known pathobiologies of T2D represent a reservoir of potential cardiovascular markers that are needed to develop the next generation of antidiabetes medications.
Authors: David Bar-Or; Kent D Heyborne; Raphael Bar-Or; Leonard T Rael; James V Winkler; Daniel Navot Journal: Prenat Diagn Date: 2005-03 Impact factor: 3.050
Authors: Dobrin Nedelkov; Urban A Kiernan; Eric E Niederkofler; Kemmons A Tubbs; Randall W Nelson Journal: Proc Natl Acad Sci U S A Date: 2005-07-25 Impact factor: 11.205
Authors: Abdul Jaleel; Panagiotis Halvatsiotis; Brian Williamson; Peter Juhasz; Stephen Martin; K Sreekumaran Nair Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112
Authors: Christopher H S McIntosh; Hans-Ulrich Demuth; Su-Jin Kim; J Andrew Pospisilik; Raymond A Pederson Journal: Int J Biochem Cell Biol Date: 2006-01-11 Impact factor: 5.085
Authors: Andrea F Lopez-Clavijo; Carlos A Duque-Daza; Andrew Soulby; Isolda Romero Canelon; Mark Barrow; Peter B O'Connor Journal: J Am Soc Mass Spectrom Date: 2014-10-15 Impact factor: 3.109
Authors: Bryan Krastins; Amol Prakash; David A Sarracino; Dobrin Nedelkov; Eric E Niederkofler; Urban A Kiernan; Randall Nelson; Maryann S Vogelsang; Gouri Vadali; Alejandra Garces; Jennifer N Sutton; Scott Peterman; Gregory Byram; Bruno Darbouret; Joëlle R Pérusse; Nabil G Seidah; Benoit Coulombe; Johan Gobom; Erik Portelius; Josef Pannee; Kaj Blennow; Vathany Kulasingam; Lewis Couchman; Caje Moniz; Mary F Lopez Journal: Clin Biochem Date: 2013-01-08 Impact factor: 3.281
Authors: Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson Journal: Proteomics Clin Appl Date: 2013-07-09 Impact factor: 3.494
Authors: Chad R Borges; Douglas S Rehder; Sally Jensen; Matthew R Schaab; Nisha D Sherma; Hussein Yassine; Boriana Nikolova; Christian Breburda Journal: Mol Cell Proteomics Date: 2014-04-15 Impact factor: 5.911
Authors: John P Savaryn; Adam D Catherman; Paul M Thomas; Michael M Abecassis; Neil L Kelleher Journal: Genome Med Date: 2013-06-27 Impact factor: 11.117